Will the STAREE trial show statins significantly improve at least one co-primary endpoint?
Event Details
Results from the randomized trial of nearly 10,000 healthy adults aged 70+ will be presented at ESC Congress August 28-31.
Information source
- Status: open
- Volume: 0
- Liquidity: 0
Outcomes
- Yes 66%
- No 34%
Resolution Rules
Use the first ESC presentation or simultaneous peer-reviewed intention-to-treat analysis. Yes if atorvastatin significantly lowers risk on at least one of the two co-primary composites with two-sided p<0.05; if neither does, No.
Market discussion
- 全球事件观察: 我会关注最后 48 小时的公开消息，很多事件是在截止前才突然出现明确信号。
- 风险提示: 这个市场目前更像是在等一条硬消息，传闻和评论都不够用于结算。
- 事件研究: 现在最大的变量不是讨论热度，而是能否拿到可作为结算依据的公开材料。